

# Mutations in the Proteolipid Subunits of the Vacuolar H<sup>+</sup>-ATPase Provide Resistance to Indolotryptoline Natural Products


Fang-Yuan Chang,<sup>†</sup> Shigehiro A. Kawashima,<sup>‡</sup> and Sean F. Brady<sup>\*,†</sup>

<sup>†</sup>Laboratory of Genetically Encoded Small Molecules, Howard Hughes Medical Institute, The Rockefeller University, 1230 York Avenue, New York, New York 10065, United States

<sup>‡</sup>Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan

## S Supporting Information

**ABSTRACT:** Indolotryptoline natural products represent a small family of structurally unique chromopyrrolic acid-derived antiproliferative agents. Like many prospective anticancer agents before them, the exploration of their potential clinical utility has been hindered by the limited information known about their mechanism of action. To study the mode of action of two closely related indolotryptolines (BE-54017, cladoniamide A), we selected for drug resistant mutants using a multidrug resistance-suppressed (MDR-sup) *Schizosaccharomyces pombe* strain. As fission yeast maintains many of the basic cancer-relevant cellular processes present in human cells, it represents an appealing model to use in determining the potential molecular target of antiproliferative natural products through resistant mutant screening. Full genome sequencing of resistant mutants identified mutations in the c and c' subunits of the proteolipid substructure of the vacuolar H<sup>+</sup>-ATPase complex (V-ATPase). This collection of resistance-conferring mutations maps to a site that is distant from the nucleotide-binding sites of V-ATPase and distinct from sites found to confer resistance to known V-ATPase inhibitors. Acid vacuole staining, cross-resistance studies, and direct c/c' subunit mutagenesis all suggest that indolotryptolines are likely a structurally novel class of V-ATPase inhibitors. This work demonstrates the general utility of resistant mutant selection using MDR-sup *S. pombe* as a rapid and potentially systematic approach for studying the modes of action of cytotoxic natural products.



A number of biologically active natural products arise from the biosynthetic coupling and subsequent oxidative rearrangement of two tryptophans (e.g., tryptophan dimers).<sup>1</sup> One rare subclass of this general family is the indolotryptolines, which are characterized by the presence of a tricyclic tryptoline fused to an indole in the final structure (Figure 1).<sup>2,3</sup> The two reported indolotryptolines, BE-54017<sup>4</sup> and cladoniamide A,<sup>5</sup> both exhibit potent (nanomolar) antiproliferative activity against diverse cancer cell lines *in vitro*. As this is one of the defining characteristics for natural products that have successfully transitioned into clinically useful cancer chemotherapy drugs,<sup>6,7</sup> these compounds have recently attracted an increasing level of interest.<sup>3,8–11</sup>

While biological studies of indolotryptolines are still in their infancy, the biological activities of the more common indolocarbazole-type natural product tryptophan dimers, which differ from indolotryptolines by the presence of a tricyclic carbazole in place of a tryptoline, have been extensively studied (Figure 1).<sup>12</sup> More than 100 natural indolocarbazoles have been discovered to date, with many showing potent *in vitro* cytotoxicity,<sup>13</sup> and both natural and synthetic derivatives of the indolocarbazoles, staurosporine and rebeccamycin, have been introduced into clinical trials as cancer therapeutic

agents.<sup>14</sup> One of the key events in the therapeutic development of indolocarbazole-related metabolites (e.g., Gleevec and others)<sup>15</sup> was the determination that although staurosporine and rebeccamycin bind unique molecular targets (e.g., protein kinase and DNA topoisomerase I, respectively), they function through a common binding motif involving their interaction at the nucleotide (i.e., ATP or DNA)-binding site of the target protein.<sup>16,17</sup>


A recent high-throughput screen for small molecule inhibitors of the vacuolar-type H<sup>+</sup>-ATPase (V-ATPase) serendipitously found that BE-54017 shows V-ATPase inhibitory activity in a human cell line.<sup>18</sup> The V-ATPase is highly conserved across eukaryotes and is responsible for pumping protons across the plasma membranes and acidifying an array of intracellular organelles.<sup>19,20</sup> As the V-ATPase is increasingly viewed as a potentially underexplored target for anticancer therapy because of the variety of pH gradients observed in cancer development,<sup>21,22</sup> we were interested in using a more systematic genome-wide approach to either genetically

Received: August 26, 2014

Revised: October 9, 2014

Published: October 15, 2014





**Figure 1.** Chemical structures of indolotryptoline (green)- and indolocarbazole (red)-containing natural product cytotoxins.


corroborate V-ATPase or possibly identify a different entity as the physiologically relevant molecular target of indolotryptolines.

Elucidating the molecular target of a bioactive small molecule in a genome-wide context remains a significant challenge.<sup>23,24</sup> This is especially true when studying cytotoxic natural products that might serve as anticancer agents. One approach for determining the mode of action of a small molecule involves the selection and full genome sequencing of mutants that acquire compound resistance.<sup>25</sup> Upon identification of resistance-conferring mutations, a compound's effect on the activity of both the mutant and wild-type gene products can be used to directly validate a proposed mode of action. This powerful approach is commonly employed for target identification of antimicrobial natural products.<sup>26,27</sup> However, its application to antitumor natural product mode of action studies has been limited because of the time-consuming, costly, and cumbersome nature of conducting these experiments using human cells.

Yeasts are often used as a eukaryotic model for antineoplastic mode of action studies because of their small genomes, fast growth rates, and genetic tractability.<sup>28</sup> While budding yeast (*Saccharomyces cerevisiae*) have usually been used in these types of studies, fission yeast (*Schizosaccharomyces pombe*) maintain many more of the basic cancer-relevant cellular processes present in human cells (e.g., cell division, DNA replication, and heterochromatin assembly), making fission yeast a potentially much more general model for mode of action studies.<sup>29</sup> However, despite the clear biological advantages fission yeast provide, resistant mutant screening has seldom been employed in *S. pombe*, because of its robust multidrug resistance (MDR) response and therefore lack of sensitivity to many cytotoxins.<sup>30</sup> A recent study identified five major contributors to fission yeast's MDR phenotype (four drug efflux transporters and a transcription factor) and showed that their deletion results in the increased sensitivity of *S. pombe* to a wide range of chemical toxins.<sup>31</sup> This MDR-suppressed (MDR-sup) strain of *S. pombe* should be particularly well suited for antiproliferative natural product target identification studies because of its broad sensitivity to cytotoxins and its weakened ability to acquire drug

resistance through uninformative, nonspecific MDR mechanisms.

Here we have used MDR-sup *S. pombe* to study the mode of action of the indolotryptoline-containing natural products, BE-54017 and cladoniamide A (Figure 2). Whole-genome



**Figure 2.** Four-step schematic for resistance screening using *S. pombe*. For mutagenesis, the *S. pombe* strain with its multidrug resistance (MDR) response suppressed (MDR-sup) through five-gene knockouts (KO) is randomly mutagenized with methylnitroimidazole (NTG). For selection, NTG-mutagenized cells are plated on drug-containing solid media to select for resistant mutants. For backcrossing, drug resistant mutants (orange) are crossed with unmutagenized MDR-sup (white), resulting in the formation of ascus containing four spore progeny with a decrease in the number of mutations. Progeny retaining drug resistance (orange) are maintained. For sequencing, the genome of each backcrossed mutant is sequenced and compared to the unmutagenized parent genome to identify the specific mutation that confers drug resistance.

sequencing of indolotryptoline resistant MDR-sup *S. pombe* mutants identified point mutations in the *c/c'* proteolipid subunits of the V-ATPase. The reintroduction of these mutations into a clean background showed that they were necessary and sufficient for indolotryptoline resistance. Fluorescent visualization of acidic vacuoles confirms that the indolotryptolines inhibit V-ATPase activity and that the mutations in the proteolipid subunits provide resistance to V-ATPase inhibitory activity by indolotryptolines. Mapping of the observed resistance-conferring mutations onto a model proteolipid structure shows that indolotryptoline-conferring mutations map to a site that is distinct from sites known to confer resistance to previously described V-ATPase inhibitors. As well as providing corroborative genetic evidence of the predicted molecular target of indolotryptoline natural products, this work demonstrates that resistant mutant screening using MDR-sup *S. pombe* can serve as a simple and generic tool for natural product mode of action studies.

## MATERIALS AND METHODS

**Reagents and Strains.** The multidrug resistance-suppressed (MDR-sup) *S. pombe*, SAK84 and SAK690, and the MDR-active *S. pombe* SAK1, from which MDR-sup *S. pombe* was derived, were generously provided by T. M. Kapoor (Laboratory of Chemistry and Cell Biology, The Rockefeller University). The genotypes<sup>32,33</sup> of these strains are listed in

Table S1 of the Supporting Information. The indolotryptoline-based compounds, BE-54017 and cladoniamide A, were isolated from *Streptomyces albus* harboring the *abe* gene cluster, as described previously.<sup>2</sup> Bafilomycin A1, concanamycin A, and brefeldin A were purchased from a commercial supplier (Santa Cruz Biotechnology).

**S. pombe Whole-Cell Cytotoxicity Assay.** Freshly struck MDR-sup *S. pombe* SAK84 was inoculated into liquid YE4S medium and grown (30 °C, 300 rpm) to log phase (OD<sub>595</sub> = 0.5). The culture was diluted 50-fold and distributed as 100 µL aliquots into a sterile 96-well microtiter plate. BE-54017 or cladoniamide A resuspended in dimethyl sulfoxide (DMSO) was added to the first well at an initial concentration of 0.50 µg/mL (1109 nM for BE-54017 and 1144 nM for Cladoniamide A) and serially diluted 2-fold across the plate (final concentrations of 0.50, 0.25, 0.13, 0.063, 0.031, 0.016, 0.0078, 0.0039, 0.0020, 0.0010, 0.00050, and 0.00025 µg/mL). A compound-free DMSO control was similarly diluted across the plate (final DMSO concentration of <1%; no effect was observed on the apparent growth rate of MDR-sup *S. pombe*). After outgrowth (36 h, 30 °C, 300 rpm), the absorbance (OD<sub>595</sub>) of each well was measured using a microplate reader (Epoch Microplate Spectrophotometer, BioTek). Using Graph-Pad Prism, the normalized absorbance values were plotted and curve-fitted to determine the half-maximal inhibitory concentration (IC<sub>50</sub>) for each indolotryptoline. The same method (using different initial drug concentrations) was used to determine IC<sub>50</sub> values for bafilomycin A1, concanamycin A, and brefeldin A against resistant and nonmutant strains.

**Selection of Indolotryptoline Resistant *S. pombe* Mutants.** Twenty milliliters of log phase *S. pombe* SAK84 was pelleted by centrifugation (3000g for 3 min) and resuspended in TM buffer [50 mM Tris, 50 mM maleic acid, 7.5 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, and 0.4 mM MgSO<sub>4</sub> (pH 6.0)] containing 50 µg/mL methylnitronitrosoguanidine (NTG) to randomly mutagenize the genome. After 30 min at 32 °C (250 rpm), the mutagenized cells were pelleted, washed twice with 10 mL of sterile water, resuspended in 20 mL of fresh YE4S, and allowed to recover for 3 h (32 °C and 250 rpm). The culture was adjusted to an OD<sub>595</sub> of 0.5, and 150 µL aliquots were spread onto YE4S plates containing different concentrations of the indolotryptolines. After 72 h at 32 °C, resistant clones were picked from plates containing either ~10 (BE-54017, 69 nM; cladoniamide A, 143 nM) or ~50 (BE-54017, 35 nM; cladoniamide A, 72 nM) colonies. Each strain was then reassessed for indolotryptoline resistance and cross-resistance to brefeldin A using the whole-cell cytotoxicity assay described above.

**Backcrossing of Indolotryptoline Resistant Mutants.** Resistant strains were crossed with nonmutant MDR-sup strain SAK690, which differs in genetic background from SAK84 only by having a different mating type (h-). Both resistant and nonmutant *S. pombe* strains grown on YE4S plates were resuspended in water to produce suspensions with an OD<sub>595</sub> of ~1. These were mixed in equal volumes, and 10 µL aliquots were spotted onto an SPA plate. After 40 h at 25 °C, the mixture was struck onto a YE4S plate. Using a dissecting microscope/micromanipulator (Axioskop 40, Zeiss), zygotic asci (mating products) were isolated from the YE4S plate and incubated (37 °C for 6 h) to permit native digestion of the ascus wall. The four spores from each zygotic ascus were then separated and individually grown on a YE4S plate (30 °C for 5 days). The resulting colonies were tested for resistance to


indolotryptolines, and resistant colonies were used in subsequent rounds of backcrossing. For additional rounds of backcrossing, the progeny that retained resistance were crossed, depending on their mating type, with either SAK84 or SAK690.

**Whole-Genome Sequencing and Bioinformatics.** Backcrossed mutants were grown in YE4S, and genomic DNA was isolated from these cultures using zymolyase treatment followed by phenol/chloroform extraction.<sup>34</sup> Genomic DNA from six resistant mutants and two nonmutant strains (SAK84 and SAK690) was sequenced at the Rockefeller University Genomics Resource Center using Illumina HiSeq 2000 technology (50 bp single end, ~150 million reads in total). Reads from resistant mutants were compared to those of nonmutant samples to identify resistant mutant specific somatic mutations that altered the wild-type amino acid sequence with ≥4× coverage and >50% mutation allele frequency. In brief, the variant detection pipeline consisted of the mapping of Illumina reads to the *S. pombe* genome<sup>29</sup> using BWA, removal of duplicates, indel-based realignment using GATK, base quality score recalibration, mutation calling for a single-nucleotide variant using a GATK Unified Genotyper, and annotation using SnpEff (Sloan Kettering Bioinformatics Core).

**Polymerase Chain Reaction (PCR) Sequencing of V-ATPase Proteolipid Subunit Genes.** A fresh colony of each resistant strain that was not sequenced by HiSeq was resuspended in 0.2% SDS and heated at 95 °C for 10 min. One microliter of this crude cell lysate was used as a template in PCRs designed to amplify the *vma3*, *vma11*, and *zhf1* genes (*Phusion Hot Start Flex* DNA polymerase kit, New England Biolabs). Primers are listed in Table S2 of the Supporting Information. The following PCR cycling conditions were used: one cycle of 95 °C for 2 min; 30 cycles of 95 °C for 10 s, 58 °C for 30 s, and 72 °C for 30 s per kilobase; one cycle for 7 min at 72 °C; and hold at 4 °C. The resulting amplicons were sequenced from both ends using the same set of primers that were used for PCR.

**Targeted Mutagenesis of the *S. pombe* Genome.** The *vma3* or *vma11* specific recombination cassettes containing point mutations of interest were amplified from the appropriate resistant mutant using the same *Phusion Hot Start Flex* PCR conditions described previously. Primers were designed (Table S2 of the Supporting Information) to generate amplicons with ~500 bp homology arms flanking each side of the point mutation of interest. The PCR cassette was introduced into SAK84 by lithium acetate-assisted transformation.<sup>34</sup> The transformation reaction mixture was spread onto YE4S plates containing defined concentrations of indolotryptoline to select for strains conferring drug resistance. The acquisition of drug resistance and point mutation were confirmed by a whole-cell cytotoxicity assay and PCR sequencing, respectively.

**V-ATPase Activity Assay by Acidic Organelle Staining.** Log phase *S. pombe* was added to fresh indolotryptoline-containing media [final concentrations of 0.50 (1109 nM for BE-54017 and 1144 nM for cladoniamide A), 0.25, 0.13, 0.063, 0.031, 0.016, 0.0078, and 0.0039 µg/mL] to give 5 mL cultures with an OD<sub>595</sub> of 0.15. These cultures were grown at 30 °C for 1 h, pelleted (2 min at 3000g), and washed with YE4S buffered with 50 mM MOPS (pH 7.6). The cell pellet was then resuspended in buffered YE4S containing 200 µM quinacrine, and staining was allowed to proceed at room temperature for 10 min. After being washed with buffered YE4S, the samples were resuspended in the same medium and transferred to an eight-chamber slide. Cells were imaged at the Rockefeller



**Figure 3.** Data from BE-54017 (B#) and cladoniamide A (C#) resistant mutant strains. Compilation of data from either (A) fully sequenced or (B) *vma3*, *vma11*, or *zhf1* PCR-sequenced resistant mutants. Genes containing mutations, the amino acid change encoded by each mutation, and the fold difference in whole-cell cytotoxicity (IC<sub>50</sub>) relative to the unmutagenized strain are shown. Abbreviations: BE, BE-54017; Cla, cladoniamide A; Baf, bafilomycin A1; Con, concanamycin A; Bre, brefeldin A; N/D, not determined. The numbers followed by asterisks represent average values. (C) Examples of dose response curves used to determine whole-cell cytotoxicity and fold differences in IC<sub>50</sub>. Curves for BE-54017 and bafilomycin A1 against mutant B1, mutant B7, or unmutagenized MDR-sup *S. pombe* are shown. See also Figure S1 and Table S3 of the Supporting Information.

University Bio-Imaging Resource Center under a fluorescent microscope using a 100× objective lens with DIC optics for Nomarski imaging or with a fluorescein isothiocyanate (FITC) filter set for quinacrine visualization (DeltaVision Image Restoration Microscope System with Olympus IX-70 base microscope, Applied Precision). A minimum inhibitory concentration (MIC) was defined as the minimum dose at which the formation of fluorescent puncta was inhibited in >95% of the cells.

**Mapping of Resistance-Confering Residues onto a V-ATPase Structure.** The *Enterococcus hirae* Na<sup>+</sup>-ATPase proteolipid subunit, NtpK [Protein Data Bank (PDB) entry 2bl2], was imaged using PyMOL. A CLUSTALW alignment of *S. pombe* V-ATPase proteolipid subunits Vma3 and Vma11 and NtpK was created to map residues between proteins from the two organisms. Residues that confer resistance to indolotryptoline and plecomacrolide compounds were identified in NtpK based on this alignment. Side chains for resistance-confering residues were converted to those seen in wild-type Vma3 or Vma11 and then represented as colored sticks on the NtpK structure.

## RESULTS

**Random Mutagenesis and Selection of Indolotryptoline Resistant MDR-sup *S. pombe* Mutants.** As an initial step in investigating the mode of action of indolotryptolines, methylnitronitrosoguanidine (NTG)-mutagenized MDR-sup *S. pombe* was plated on medium containing either BE-54017 or cladoniamide A (Figure 2). For both metabolites, concentrations ranging from 2- to 6-fold above the IC<sub>50</sub> (BE-54017, 35–70 nM; cladoniamide A, 70–150 nM) were used for resistant mutant selections, which yielded between 1 and 10 resistant colonies per 100000 mutagenized cells. In contrast, the *S. pombe* strain from which MDR-sup *S. pombe* was derived (MDR-active *S. pombe*) is approximately 50 times less sensitive to these natural products (IC<sub>50</sub> values of 780 nM for BE-54017 and 1600 nM for cladoniamide A). For each target compound, we picked 12 resistant colonies for further analysis (*S. pombe*

strains B1–B12 for BE-54017 and *S. pombe* strains C1–12 for cladoniamide A). These 24 mutants were re-examined for indolotryptoline resistance and tested for cross-resistance to the unrelated cytotoxin, brefeldin A (protein transport inhibitor). Strains that failed to show resistance when they were rescreened against indolotryptolines (B2, B9, C1, and C11) and those showing cross-resistance to brefeldin A (C7) were abandoned. All of the remaining strains were found to be resistant to both BE-54017 and cladoniamide A, suggesting a common mode of action and drug-binding site. The IC<sub>50</sub> for these resistant mutants ranged from 2- to 8-fold above the IC<sub>50</sub> determined for unmutagenized MDR-sup *S. pombe* (Figure 3 and Figure S1 of the Supporting Information).

**Characterization of Indolotryptoline Resistance-Confering Mutations by Backcrossing and Sequencing.** Random NTG mutagenesis can result in the introduction of multiple mutations into the genome of each strain, complicating the identification of the specific mutations that are relevant to the molecular target. An additional benefit of using fission yeast as a model for the resistance selection approach is that the complexity of the mutagenized genetic background can be significantly simplified through backcrossing with unmutagenized yeast (Figure 2). Backcrossing serves to replace non-drug resistance-associated mutations with wild-type alleles from the unmutagenized strain, thereby preventing irrelevant mutations from complicating downstream genome-wide bioinformatics analyses. Six representative mutant strains showing varying levels of resistance (B1, B5, B7, B12, C3, and C6) were backcrossed four to six times with unmutagenized MDR-sup *S. pombe* (Figure 3). Consistently, two of the four progeny from each backcross retained drug resistance, suggesting that a single mutation was responsible for the observed resistant phenotype in each strain. The final backcrossed clones were subjected to Illumina whole-genome sequencing, and the resulting reads were mapped onto the unmutagenized MDR-sup genome to identify differences in protein-coding sequences. Upon comparison to the unmutagenized MDR-sup genome, the six backcrossed strains were found to contain between one and


four point mutations (Figure 3A). While various one-off mutations (e.g., *qcr6* in B1 and *apl5* in B5) were observed in this strain collection, every resistant strain had mutations either in the zinc transporter gene, *zhf1* (B1, B5, and C3), or in genes encoding the c (*vma3* for B7 and B12) or c' (*vma11* for C6) subunits of the vacuolar H<sup>+</sup>-ATPase complex (V-ATPase), suggesting that zinc transporter and V-ATPase activity were likely linked to the molecular mechanism of indolotryptoline cytotoxicity. In no cases did we detect mutations that might traditionally be associated with a generic MDR-like phenotype, highlighting a key advantage of using the MDR-sup strain.

The *zhf1*, *vma3*, and *vma11* genes from the 13 resistant strains that were not analyzed by Illumina whole-genome sequencing were amplified via PCR and individually sequenced (Figure 3B). All 13 strains were found to contain a mutation in one of these three genes. Eight strains contain the same *zhf1* mutation (W324L) observed previously, making it the most common mutation we detected. Four strains contain new variants of *vma3* (C8), *vma11* (B10 and C12), and *zhf1* (B3), and the remaining strain B11 has the same *vma11* mutation that is seen in C6.

**Targeted Mutagenesis of V-ATPase and Zinc Transporter Genes.** The genetic tractability of yeast allows for a specific mutation of interest to be easily introduced into a clean background to provide a genetic validation of its role in conferring resistance. To confirm the relevance of the *vma* and *zhf* mutations to indolotryptoline resistance, each unique *vma3*/11 point mutation (B7, B10, B12, C6, and C8) and the common W324L *zhf1* mutation (B1) were introduced into the unmutagenized MDR-sup *S. pombe* strain by homologous recombination. The resulting strains, which were shown by PCR amplicon sequencing to harbor the desired mutation, were all found to be resistant to indolotryptolines at the same level as the randomly mutagenized clones containing the same mutation (Figure S2 of the Supporting Information). The individual *vma3*, *vma11*, and *zhf* mutations we detected are therefore necessary and sufficient for conferring resistance to indolotryptoline-based compounds.

**Acidic Staining of Vacuoles.** As the V-ATPase is responsible for maintaining the acidification of cellular organelles, V-ATPase activity can be monitored in whole cells by using acidic staining dyes (e.g., quinacrine) that form fluorescent puncta in vacuoles at reduced pH.<sup>35,36</sup> Similar to the known plecomacrolide-type V-ATPase inhibitors, bafilomycin and concanamycin, indolotryptolines also prevented the formation of fluorescent puncta in the cells in a dose-dependent manner, while the presence of brefeldin (protein transport inhibitor) had no effect (Figure 4A). Whole-cell V-ATPase inhibition by indolotryptolines (MICs of 69 nM for BE-54017 and 143 nM for cladoniamide A) occurs at concentrations similar to those needed for whole-cell cytotoxicity (MICs of 35 nM for BE-54017 and 72 nM for cladoniamide A). In addition, acidic staining experiments were conducted using strains containing each unique *vma3* (B7, B12, and C8) and *vma11* (B10 and C6) mutation, as well as a representative strain with the common W324L *zhf1* (B1) mutation (Figure 4B and Figure S3 of the Supporting Information). All *vma3* and *vma11* mutants showed increased tolerance to the disruption of puncta by indolotryptolines, while the *zhf1* mutant responded like nonmutant MDR-sup in these experiments.


**V-ATPase Inhibition in the Presence of Zinc.** As Zhf1 is responsible for controlling zinc homeostasis, in particular in regulating the zinc concentration in the endoplasmic reticulum



**Figure 4.** Visualization of whole-cell V-ATPase activity by acidic organelle staining. (A) Nomarski and fluorescent images of quinacrine-stained unmutagenized MDR-sup *S. pombe* upon incubation with BE-54017 (BE) or brefeldin A (Bre). The formation of fluorescent puncta is inhibited at higher concentrations of BE, with no puncta observed in >95% of the cells at 69 nM, which is defined as the minimum inhibitory concentration (MIC) of V-ATPase activity (red). Bre has no effect on puncta formation. (B) Summary of the fold difference in whole-cell V-ATPase MIC relative to unmutagenized MDR-sup. Cla, cladoniamide A. See also Figure S3 and Table S3 of the Supporting Information.

and nucleus, we tested the relationship between indolotryptoline toxicity and zinc concentration. In these assays, we observed that MDR-sup *S. pombe* becomes more sensitive to BE-54017 and cladoniamide A with increasing concentrations of zinc in the growth medium (Figure 5). This effect is similarly observed with the known V-ATPase inhibitors, bafilomycin and concanamycin, but not with the protein transport inhibitor, brefeldin.


**Cross-Resistance.** Indolotryptoline resistant strains were tested for cross-resistance to the well-characterized plecomacrolide-type V-ATPase inhibitors, bafilomycin and concanamycin.



**Figure 5.** Sensitivity of the unmutagenized MDR-sup *S. pombe* to cytotoxins in the presence of increasing concentrations of zinc. (A) Summary of fold differences in whole-cell cytotoxicity (IC<sub>50</sub>) relative to media without the addition of ZnCl<sub>2</sub>. (B) Dose response curve for unmutagenized MDR-sup when it is exposed to BE-54017 in the presence of different concentrations of ZnCl<sub>2</sub>. In the tested ZnCl<sub>2</sub> concentration range (0.01–0.2 mM), zinc has no effect on the apparent growth rate of MDR-sup *S. pombe* in the absence of any cytotoxins. See also Table S3 of the Supporting Information.

cin (Figure 3 and Figure S1 of the Supporting Information). The W324L Zhf1 mutant confers resistance to both of the known V-ATPase inhibitors. With the exception of the M130I Vma3 (C8) mutant, which confers a 2-fold increase in resistance to bafilomycin, V-ATPase mutants did not show cross-resistance to either bafilomycin or concanamycin.

**Mapping of the Putative Indolotryptoline Proteolipid-Binding Site.** The V-ATPase is a multiprotein complex that consists of two domains: a peripheral ATP-binding domain ( $V_1$ ) and a membrane-associated proton translocating pore domain ( $V_0$ ) (Figure 6A).<sup>19,20</sup> In yeast, the  $V_0$  domain contains



**Figure 6.** Structure of V-ATPase. (A) Schematic of yeast V-ATPase architecture, which consists of the catalytic  $V_1$  domain (green) and the membrane-translocating  $V_0$  domain (yellow and beige). Proteolipid subunits c, c', and c'' (beige) are part of the  $V_0$  domain and form a hexameric ring structure. (B–D) Side, close-up, and top views, respectively, of the crystal structure of a proteolipid subunit from the *E. hirae* V-ATPase (PDB entry 2BL2). The peptide backbone is represented as a green stick model. Residues found to be involved in conferring resistance to indolotryptolines are colored red. Residues reported in previous studies to be involved in plecomacrolide resistance are colored blue.<sup>37</sup> See also Figure S4 of the Supporting Information.

a hexameric cylinder that is known as the proteolipid ring. The catalytic  $V_1$  subunit hydrolyzes ATP, which drives the rotation of the proteolipid ring that in turn allows for protons to translocate across the membrane. The proteolipid ring is thought to be composed of c (*vma3*), c' (*vma11*), and c'' (*vma16*) subunits that assemble in a 4:1:1 (c:c':c'') stoichiometry.<sup>19,20,37</sup> As is the case with plecomacrolide resistance-conferring mutations, indolotryptoline-conferring mutations are found in the proteolipid subunits.

The detailed molecular structure of the yeast V-ATPase is not known; however, the proteolipid substructure from the vacuolar  $Na^+$ -ATPase from the bacterium *E. hirae* has been determined by X-ray crystallography.<sup>38</sup> Despite phylogenetic and functional differences, the high degree of sequence homology seen between the *E. hirae* proteolipid subunits and


those found in eukaryotic V-ATPase complexes has led to the use of the *E. hirae* V-ATPase structure as a model for eukaryotic V-ATPase studies. In particular, the residues that confer resistance to V-ATPase inhibitors have been mapped onto the *E. hirae* V-ATPase structure to predict putative inhibitor-binding sites.<sup>37,39</sup> Residues reported to confer resistance to plecomacrolide-like inhibitors generally cluster midway between the cytoplasmic and luminal faces of the proteolipid ring and point out from the four-helix bundle that makes up each of the proteolipid subunits.<sup>37</sup> In contrast, indolotryptoline resistance-conferring mutations map near the cytoplasmic face and mostly point into the center of the bundle (Figure 6 and Figure S4 of the Supporting Information).

## DISCUSSION

Through whole-genome sequencing of indolotryptoline resistant mutants, we identified point mutations in the proteolipid (c/c') subunits of V-ATPase and the zinc transporter Zhf1 that conferred resistance to this family of natural products. Previous studies have observed a tight functional connection between zinc toxicity and V-ATPase activity. The inactivation of the V-ATPase in diverse organisms from yeasts to plants, by either a gene knockout or a small-molecule inhibitor, is known to result in increased sensitivity to zinc, indicating that the V-ATPase plays a critical role in zinc homeostasis and that zinc toxicity is likely the principal downstream deleterious consequence of V-ATPase inhibition.<sup>40–42</sup> As would be expected for a V-ATPase inhibitor, we observed that MDR-sup *S. pombe* becomes more sensitive to indolotryptolines in the presence of increasing concentrations of zinc.

Although V-ATPase activity in budding yeast (*Sa. cerevisiae*) has been investigated *in vitro* using isolated vacuolar membranes,<sup>43</sup> the purification of similar membrane fractions from *S. pombe* has proven to be challenging, thereby precluding comparable *in vitro* biochemical analyses of these mutants.<sup>44</sup> However, because the V-ATPase is responsible for maintaining the acidification of cellular organelles, V-ATPase activity in whole cells can be monitored using acidic staining dyes.<sup>35,36</sup> As previously reported for known V-ATPase inhibitors,<sup>45,46</sup> the addition of indolotryptolines to culture media at subminimal inhibitory concentrations resulted in the loss of fluorescent puncta formation in a dose-dependent manner in unmutagenized MDR-sup *S. pombe* (Figure 5A), confirming the inhibition of V-ATPase activity in the presence of indolotryptolines. The fact that our indolotryptoline resistance-conferring V-ATPase mutants are largely compound class specific, while Zhf1 mutants confer resistance irrespective of the compound class, further suggests a model in which zinc toxicity is a downstream deleterious consequence of V-ATPase inhibition in the presence of indolotryptoline natural products. Ultimately, the *in vitro* biochemical reconstitution of mutant and wild-type human V-ATPase will be necessary to definitively confirm V-ATPase as the molecular target of indolotryptolines in human cells.

The V-ATPase is a highly conserved protein complex in eukaryotes that plays a role in acidifying a variety of organelles.<sup>19,20</sup> V-ATPase inhibitors have been explored as cancer therapeutic agents because of their cytotoxicity toward diverse cancer cell lines.<sup>47,48</sup> Cell lines from cancers that are especially malignant, aggressive, and unresponsive to current therapies are known to be sensitive to V-ATPase inhibitors, possibly because of the involvement of an acid microenviron-



**Figure 7.** Chemical structures of previously characterized V-ATPase inhibitors.

ment in tumor progression and multidrug resistance.<sup>21,22</sup> On the basis of the fact that four of the five *vma3/11* mutations that confer resistance to indolotryptolines do not show cross-resistance to plecomacrolide-type metabolites and that the fifth mutation confers only low-level resistance to bafilomycin (Figure 3), the indolotryptoline-binding site is likely distinct from the plecomacrolide-binding pocket in the proteolipid ring. On the basis of the significant structural differences between indolotryptolines and known V-ATPase inhibitors (Figure 7),<sup>49</sup> it would not be surprising that they bind at a distinct site and therefore have selected for unique resistance-conferring mutations. The potential existence of a unique indolotryptoline V-ATPase-binding site suggests that these natural products can serve as the inspiration for the development of a new class of nanomolar V-ATPase inhibitors that can be explored for anticancer activity.

Tryptophan dimers, in particular the closely related indolocarbazole family of natural products, have been observed to interact with proteins containing nucleotide-binding sites (i.e., ATP or DNA) through mimicry of a nucleotide base.<sup>13,15–17</sup> While the V-ATPase uses ATP, the proteolipid subunits of V-ATPase are not known to contain a nucleotide-binding site, suggesting that tryptophan dimer-binding motifs might extend beyond simple nucleotide mimicry. Disruption of the planar indolocarbazole ring system through the  $sp^3$  hybridization of the two carbons at the base of the pyrrole ring in the indolotryptoline structure is likely to lead to an altered mode of binding of this class of tryptophan dimers. Eventually, an indolotryptoline–proteolipid cocrystal structure will be required to confirm this change in binding motif hypothesis.

Any molecular target elucidated in a model organism like *S. pombe* must ultimately be confirmed in human cancer cells if relevance to cancer therapy is to be established. Nevertheless, resistant mutant selection of MDR-sup *S. pombe* provides the means for developing mode of action hypotheses that do not require any chemical modification of the bioactive compound,

preliminary prediction of the target, or construction of a custom-made genetic library, thereby serving as a convenient alternative approach for target identification studies of cytotoxic natural products. The characterization of a cytotoxic natural product's molecular target using human cells has traditionally been costly, time-consuming, and technically cumbersome. Resistant mutant screening using MDR-sup *S. pombe* should serve as a powerful and generally applicable alternative target identification technique that fits nicely into diverse drug discovery pipelines for gene-level target identification and validation of cytotoxins.

## ■ ASSOCIATED CONTENT

### ⑤ Supporting Information

Complete whole-cell cytotoxicity dose response curves, targeted mutagenesis data, complete V-ATPase activity data, and protein sequence alignment of resistance-conferring mutations (Figures S1–S4, respectively) and *S. pombe* strain list, PCR primer list, and summary of IC<sub>50</sub> and MIC values (Tables S1–S3, respectively). This material is available free of charge via the Internet at <http://pubs.acs.org>.

## ■ AUTHOR INFORMATION

### Corresponding Author

\*E-mail: [sbrady@rockefeller.edu](mailto:sbrady@rockefeller.edu).

### Funding

This work was supported by National Institutes of Health Grant GM077516. S.F.B. is a Howard Hughes Medical Institute Early Career Scientist.

### Notes

The authors declare no competing financial interest.

## ■ ACKNOWLEDGMENTS

We thank Dr. Tarun M. Kapoor for the generous gift of *S. pombe* strains.

## REFERENCES

- (1) Ryan, K. S., and Drennan, C. L. (2009) Divergent pathways in the biosynthesis of bisindole natural products. *Chem. Biol.* 16 (4), 351–364.
- (2) Chang, F. Y., and Brady, S. F. (2011) Cloning and characterization of an environmental DNA-derived gene cluster that encodes the biosynthesis of the antitumor substance BE-54017. *J. Am. Chem. Soc.* 133 (26), 9996–9999.
- (3) Du, Y. L., Ding, T., Patrick, B. O., and Ryan, K. S. (2013) Xenocladoniamide F, minimal indolotryptoline from the cladoniamide pathway. *Tetrahedron Lett.* 54 (41), S635–S638.
- (4) Nakase, K.; Nakajima, S.; Hirayama, M.; Kondo, H.; Kojiri, K.; Suda, H. JP 2000178274, 2000.
- (5) Williams, D. E., Davies, J., Patrick, B. O., Botttriell, H., Tarling, T., Roberge, M., and Andersen, R. J. (2008) Cladoniamides A-G, tryptophan-derived alkaloids produced in culture by *Streptomyces unialis*. *Org. Lett.* 10 (16), 3501–3504.
- (6) Cragg, G. M., Grothaus, P. G., and Newman, D. J. (2009) Impact of natural products on developing new anti-cancer agents. *Chem. Rev.* 109 (7), 3012–3043.
- (7) Boyd, M. R., and Paull, K. D. (1995) Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. *Drug Dev. Res.* 34 (2), 91–109.
- (8) Du, Y. L., Ding, T., and Ryan, K. S. (2013) Biosynthetic O-methylation protects cladoniamides from self-destruction. *Org. Lett.* 15 (10), 2538–2541.
- (9) Ngernmeesri, P., Soonkit, S., Konkhum, A., and Kongkathip, B. (2014) Formal synthesis of (±)-cladoniamide G. *Tetrahedron Lett.* 55 (9), 1621–1624.
- (10) Loosley, B. C., Andersen, R. J., and Dake, G. R. (2013) Total synthesis of cladoniamide G. *Org. Lett.* 15 (5), 1152–1154.
- (11) Chang, F. Y., and Brady, S. F. (2013) Discovery of indolotryptoline antiproliferative agents by homology-guided meta-genomic screening. *Proc. Natl. Acad. Sci. U.S.A.* 110 (7), 2478–2483.
- (12) Speck, K., and Magauer, T. (2013) The chemistry of isoindole natural products. *Beilstein J. Org. Chem.* 9, 2048–2078.
- (13) Sanchez, C., Mendez, C., and Salas, J. A. (2006) Indolocarbazole natural products: Occurrence, biosynthesis, and biological activity. *Nat. Prod. Rep.* 23 (6), 1007–1045.
- (14) Butler, M. S. (2005) Natural products to drugs: Natural product derived compounds in clinical trials. *Nat. Prod. Rep.* 22 (2), 162–195.
- (15) Nakano, H., and Omura, S. (2009) Chemical biology of natural indolocarbazole products: 30 years since the discovery of staurosporine. *J. Antibiot.* 62 (1), 17–26.
- (16) Prade, L., Engh, R. A., Girod, A., Kinzel, V., Huber, R., and Bossemeyer, D. (1997) Staurosporine-induced conformational changes of cAMP-dependent protein kinase catalytic subunit explain inhibitory potential. *Structure* 5 (12), 1627–1637.
- (17) Staker, B. L., Feese, M. D., Cushman, M., Pommier, Y., Zembower, D., Stewart, L., and Burgin, A. B. (2005) Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. *J. Med. Chem.* 48 (7), 2336–2345.
- (18) Kimura, T., Kanagaki, S., Matsui, Y., Imoto, M., Watanabe, T., and Shibasaki, M. (2012) Synthesis and assignment of the absolute configuration of indenotryptoline bisindole alkaloid BE-54017. *Org. Lett.* 14 (17), 4418–4421.
- (19) Jefferies, K. C., Cipriano, D. J., and Forgac, M. (2008) Function, structure and regulation of the vacuolar (H<sup>+</sup>)-ATPases. *Arch. Biochem. Biophys.* 476 (1), 33–42.
- (20) Benlekbi, S., Bueler, S. A., and Rubinstein, J. L. (2012) Structure of the vacuolar-type ATPase from *Saccharomyces cerevisiae* at 11-Å resolution. *Nat. Struct. Mol. Biol.* 19 (12), 1356–1362.
- (21) Perez-Sayans, M., Somoza-Martin, J. M., Barros-Angueira, F., Rey, J. M., and Garcia-Garcia, A. (2009) V-ATPase inhibitors and implication in cancer treatment. *Cancer Treat. Rev.* 35 (8), 707–713.
- (22) Spugnini, E. P., Citro, G., and Fais, S. (2010) Proton pump inhibitors as anti vacuolar-ATPases drugs: A novel anticancer strategy. *J. Exp. Clin. Cancer Res.* 29, 44.
- (23) Schenone, M., Dancik, V., Wagner, B. K., and Clemons, P. A. (2013) Target identification and mechanism of action in chemical biology and drug discovery. *Nat. Chem. Biol.* 9 (4), 232–240.
- (24) Ziegler, S., Pries, V., Hedberg, C., and Waldmann, H. (2013) Target identification for small bioactive molecules: Finding the needle in the haystack. *Angew. Chem., Int. Ed.* 52 (10), 2744–2792.
- (25) O'Neill, A. J., and Chopra, I. (2004) Preclinical evaluation of novel antibacterial agents by microbiological and molecular techniques. *Expert Opin. Invest. Drugs* 13 (8), 1045–1063.
- (26) Delgado, M. A., Rintoul, M. R., Farias, R. N., and Salomon, R. A. (2001) *Escherichia coli* RNA polymerase is the target of the cyclopeptide antibiotic microcin J25. *J. Bacteriol.* 183 (15), 4543–4550.
- (27) Freiberg, C., Brunner, N. A., Schiffer, G., Lampe, T., Pohlmann, J., Brands, M., Raabe, M., Habich, D., and Ziegelbauer, K. (2004) Identification and characterization of the first class of potent bacterial acetyl-CoA carboxylase inhibitors with antibacterial activity. *J. Biol. Chem.* 279 (25), 26066–26073.
- (28) Goffeau, A., Barrell, B. G., Bussey, H., Davis, R. W., Dujon, B., Feldmann, H., Galibert, F., Hoheisel, J. D., Jacq, C., Johnston, M., Louis, E. J., Mewes, H. W., Murakami, Y., Philippsen, P., Tettelin, H., and Oliver, S. G. (1996) Life with 6000 genes. *Science* 274 (5287), 546–563.
- (29) Wood, V., Gwilliam, R., Rajandream, M. A., Lyne, M., Lyne, R., Stewart, A., Sgouros, J., Peat, N., Hayles, J., Baker, S., Basham, D., Bowman, S., Brooks, K., Brown, D., Brown, S., Chillingworth, T., Churcher, C., Collins, M., Connor, R., Cronin, A., Davis, P., Feltwell, T., Fraser, A., Gentles, S., Goble, A., Hamlin, N., Harris, D., Hidalgo, J., Hodgson, G., Holroyd, S., Hornsby, T., Howarth, S., Huckle, E. J., Hunt, S., Jagels, K., James, K., Jones, L., Jones, M., Leather, S., McDonald, S., McLean, J., Mooney, P., Moule, S., Mungall, K., Murphy, L., Niblett, D., Odell, C., Oliver, K., O'Neil, S., Pearson, D., Quail, M. A., Rabinowitsch, E., Rutherford, K., Rutter, S., Saunders, D., Seeger, K., Sharp, S., Skelton, J., Simmonds, M., Squares, R., Squares, S., Stevens, K., Taylor, K., Taylor, R. G., Tivey, A., Walsh, S., Warren, T., Whitehead, S., Woodward, J., Volckaert, G., Aert, R., Robben, J., Grymonprez, B., Weltjens, L., Vanstreels, E., Rieger, M., Schafer, M., Muller-Auer, S., Gabel, C., Fuchs, M., Dusterhoft, A., Fritz, C., Holzer, E., Moestl, D., Hilbert, H., Borzym, K., Langer, I., Beck, A., Lehrach, H., Reinhardt, R., Pohl, T. M., Eger, P., Zimmermann, W., Wedler, H., Wambutt, R., Purnelle, B., Goffeau, A., Cadieu, E., Dreano, S., Gloux, S., Lelaure, V., Mottier, S., Galibert, F., Aves, S. J., Xiang, Z., Hunt, C., Moore, K., Hurst, S. M., Lucas, M., Rochet, M., Gaillardin, C., Tallada, V. A., Garzon, A., Thode, G., Daga, R. R., Cruzado, L., Jimenez, J., Sanchez, M., del Rey, F., Benito, J., Dominguez, A., Revuelta, J. L., Moreno, S., Armstrong, J., Forsburg, S. L., Cerutti, L., Lowe, T., McCombie, W. R., Paulsen, I., Potashkin, J., Shpakovski, G. V., Ussery, D., Barrell, B. G., and Nurse, P. (2002) The genome sequence of *Schizosaccharomyces pombe*. *Nature* 415 (6874), 871–880.
- (30) Wolfger, H., Mamnun, Y. M., and Kuchler, K. (2001) Fungal ABC proteins: Pleiotropic drug resistance, stress response and cellular detoxification. *Res. Microbiol.* 152 (3–4), 375–389.
- (31) Kawashima, S. A., Takemoto, A., Nurse, P., and Kapoor, T. M. (2012) Analyzing fission yeast multidrug resistance mechanisms to develop a genetically tractable model system for chemical biology. *Chem. Biol.* 19 (7), 893–901.
- (32) Aoi, Y., Sato, M., Sutani, T., Shirahige, K., Kapoor, T. M., and Kawashima, S. A. (2014) Dissecting the first and the second meiotic divisions using a marker-less drug-hypersensitive fission yeast. *Cell Cycle* 13 (8), 1327–1334.
- (33) Kawashima, S. A., Takemoto, A., Nurse, P., and Kapoor, T. M. (2013) A chemical biology strategy to analyze rheostat-like protein kinase-dependent regulation. *Chem. Biol.* 20 (2), 262–271.
- (34) Alfa, C., Fantes, P., Hyams, J., McLeod, M., and Warbrick, E. (1993) *Experiments with Fission Yeast*, Cold Spring Harbor Laboratory Press, Plainview, NY.
- (35) Iwaki, T., Goa, T., Tanaka, N., and Takegawa, K. (2004) Characterization of *Schizosaccharomyces pombe* mutants defective in

vacuolar acidification and protein sorting. *Mol. Genet. Genomics* 271 (2), 197–207.

(36) Roberts, C. J., Raymond, C. K., Yamashiro, C. T., and Stevens, T. H. (1991) Methods for studying the yeast vacuole. *Methods Enzymol.* 194, 644–661.

(37) Bowman, B. J., McCall, M. E., Baertsch, R., and Bowman, E. J. (2006) A model for the proteolipid ring and bafilomycin/concanamycin-binding site in the vacuolar ATPase of *Neurospora crassa*. *J. Biol. Chem.* 281 (42), 31885–31893.

(38) Murata, T., Yamato, I., Kakinuma, Y., Leslie, A. G., and Walker, J. E. (2005) Structure of the rotor of the V-type Na<sup>+</sup>-ATPase from *Enterococcus hirae*. *Science* 308 (5722), 654–659.

(39) Bockelmann, S., Menche, D., Rudolph, S., Bender, T., Grond, S., von Zezschwitz, P., Muench, S. P., Wieczorek, H., and Huss, M. (2010) Archazolid A binds to the equatorial region of the c-ring of the vacuolar H<sup>+</sup>-ATPase. *J. Biol. Chem.* 285 (49), 38304–38314.

(40) MacDiarmid, C. W., Milanick, M. A., and Eide, D. J. (2002) Biochemical properties of vacuolar zinc transport systems of *Saccharomyces cerevisiae*. *J. Biol. Chem.* 277 (42), 39187–39194.

(41) Kawachi, M., Kobae, Y., Mimura, T., and Maeshima, M. (2008) Deletion of a histidine-rich loop of AtMTP1, a vacuolar Zn<sup>2+</sup>/H<sup>+</sup> antiporter of *Arabidopsis thaliana*, stimulates the transport activity. *J. Biol. Chem.* 283 (13), 8374–8383.

(42) Melin, P., Schnurer, J., and Wagner, E. G. (2004) Disruption of the gene encoding the V-ATPase subunit A results in inhibition of normal growth and abolished sporulation in *Aspergillus nidulans*. *Microbiology* 150 (Part 3), 743–748.

(43) Kane, P. M., Yamashiro, C. T., and Stevens, T. H. (1989) Biochemical characterization of the yeast vacuolar H<sup>+</sup>-ATPase. *J. Biol. Chem.* 264 (32), 19236–19244.

(44) Pongcharoen, P., Kawano-Kawada, M., Iwaki, T., Sugimoto, N., Sekito, T., Akiyama, K., Takegawa, K., and Kakinuma, Y. (2013) Functional expression of *Schizosaccharomyces pombe* Vba2p in the vacuolar membrane of *Saccharomyces cerevisiae*. *Biosci., Biotechnol., Biochem.* 77 (9), 1988–1990.

(45) Liu, M., Tarsio, M., Charsky, C. M., and Kane, P. M. (2005) Structural and functional separation of the N- and C-terminal domains of the yeast V-ATPase subunit H. *J. Biol. Chem.* 280 (44), 36978–36985.

(46) Marceau, F., Bawolak, M. T., Bouthillier, J., and Morissette, G. (2009) Vacuolar ATPase-mediated cellular concentration and retention of quinacrine: A model for the distribution of lipophilic cationic drugs to autophagic vacuoles. *Drug Metab. Dispos.* 37 (12), 2271–2274.

(47) Bowman, E. J., and Bowman, B. J. (2005) V-ATPases as drug targets. *J. Bioenerg. Biomembr.* 37 (6), 431–435.

(48) Fais, S., De Mito, A., You, H. Y., and Qin, W. X. (2007) Targeting vacuolar H<sup>+</sup>-ATPases as a new strategy against cancer. *Cancer Res.* 67 (22), 10627–10630.

(49) Huss, M., and Wieczorek, H. (2009) Inhibitors of V-ATPases: Old and new players. *J. Exp. Biol.* 212 (Part 3), 341–346.